In EGFR and KRAS-wild type adenocarcinomas (EGFRwt/KRASwt), different potential drivers of pathogenesis exist, including ALK, RET, and ROS1 gene fusions, with ALK rearrangements being therapeutically relevant [5-7]. This evidence concerns the gene RET and adenocarcinoma.